Clinical Trial Update: Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated oral antiviral regimens that include GS-5885 (ledipasvir), Tegobuvir, and/or GS-9451, in combination with peginterferon alfa-2a and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-5885 (GS-5885)
• GS-9451 (GS-9451)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Tegobuvir (Tegobuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED